Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World April 2009 Derek Lowe	Column: In the pipeline The author considers the problems of addressing drug development out of sequence
Chemistry World March 2012	Lead-oriented synthesis Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World May 20, 2015 Katrina Kramer	Taking the lead on drug discovery Researchers from the UK have developed a straightforward strategy for making compounds that have the potential to become clinical drugs.
Chemistry World July 2009 Derek Lowe	Column: In the pipeline The author wonders where we'd be without the formulation chemists
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Chemistry World November 6, 2009 Phillip Broadwith	Enzyme binds both sides of the mirror European chemists have discovered that both mirror-image forms of a particular compound can bind at the same time in the same site of an enzyme, a phenomenon that has never been seen before.
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World September 25, 2015 Derek Lowe	Spice up your compounds You and your team are optimizing a lead compound, as medicinal chemists are wont to do -- varying its structure to improve its potency, selectivity and other properties.
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World June 2008	Column: In the pipeline The author, a medicinal chemist working on preclinical drug discovery, takes a look at the differences between chemists and biologists working on the same team.
Chemistry World December 2007 Derek Lowe	Column: In the Pipeline The challenge of biologics.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Bio-IT World Jul/Aug 2006 Eric K. Neumann	Combining Drug Toxicity Knowledge Nearly half the drugs entering clinical trials will fail because of some form of serious toxicity that was missed in preclinical studies. These failures should not happen at such a late stage in the process. So what can be done?
Bio-IT World September 2006 Kevin Davies	Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
Chemistry World February 8, 2006 Jon Evans	To Boldly go Where no Chemist Has Gone Before Studying the interactions between different molecular fragments is taking researchers to the uncharted regions of chemical space.
Chemistry World March 9, 2006 Katharine Sanderson	Covalent Bonds Crack Under the Strain Chemists must consider engineering principles when designing molecules following news that tough carbon-to-carbon bonds break easily under mechanical strain.
Bio-IT World April 2007 Vicki Glaser	Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.
Chemistry World January 2011	Column: In the pipeline Some medicinal chemists can't get enough fluorines in their molecules. The love-hate relationship is explained.
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Bio-IT World Dec 2006/Jan 2007 Giacomo Bastianelli	The Future of Predictive Biology Predictive biology, data and the integration of disparate research disciplines are key ingredients for the future of drug discovery research and healthcare.
Chemistry World July 22, 2015 Judy Hayler	The handbook of medicinal chemistry: principles and practice The handbook of medicinal chemistry: principles and practice guides the reader through the R&D process from target validation to late stage clinical trials, via a series of chapters written by individuals in industry and academia.
Bio-IT World April 16, 2004 Kevin Davies	The Matrix Revolutions Serenex, a company dedicated to drug discovery, uses a proprietary matrix, or affinity media, to bind purine-binding protiens - a process that could transform the drug discovery business.
Chemistry World January 20, 2014 David Bradley	Molecular librarians create druglike collections Finding biologically active small molecules with pharmaceutical potential is a bittersweet process. Now, a new approach to building libraries of diverse alkaloid-type structures has been developed by US chemists.
Chemistry World June 2007 Derek Lowe	Opinion: In the Pipeline A medicinal chemist experienced in pre-clinical drug discovery sets the record straight about pharmaceutical patents on traditional medicines.
Bio-IT World February 10, 2003 Malorye Branca	Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic.
Chemistry World December 17, 2012 Patrick Walter	RSC acquires rights to Merck Index The Royal Society of Chemistry has acquired the rights to the 'bible' of chemistry, the Merck Index, familiar around the world to medicinal chemists and drug discovery scientists.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Chemistry World May 29, 2015 Derek Lowe	Magic molecule modifiers The synthesis of a new organic molecule can be approached in several ways.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.
Chemistry World June 23, 2015 Derek Lowe	Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Reactive Reports Issue 41 David Bradley	Chip Chops Time off Drug Discovery Process A next-generation optical screening platform can screen a vast number of compounds rapidly by passing wave after wave of compounds in solution over the surface of the biochip.
Chemistry World April 2007 Derek Lowe	Opinion: In the Pipeline Natural products can be ridiculously complicated. The sheer difficulty of the enterprise is traditionally what made pharmaceutical companies hire people who had worked in total synthesis. But, is total synthesis research still worth the effort?
Chemistry World May 2007 Derek Lowe	In the Pipeline After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry.